keyword
https://read.qxmd.com/read/33434154/risk-factors-and-management-of-pasireotide-associated-hyperglycemia-in-acromegaly
#1
Mônica R Gadelha, Feng Gu, Marcello D Bronstein, Thierry C Brue, Maria Fleseriu, Ilan Shimon, Aart J van der Lely, Shoba Ravichandran, Albert Kandra, Alberto M Pedroncelli, Annamaria A L Colao
Pasireotide, a multireceptor-targeted somatostatin analog with highest affinity for somatostatin receptor subtype (SST) 5, has demonstrated superior efficacy over the SST2-preferential somatostatin analogs octreotide and lanreotide. The safety profile is similar to those of octreotide and lanreotide, except for a higher frequency and degree of hyperglycemia. This analysis investigated baseline characteristics and occurrence and management of hyperglycemia during pasireotide treatment in patients with acromegaly treated in two prospective clinical studies, SOM230C2305 (C2305) and SOM230C2402 (C2402; PAOLA)...
December 2020: Endocrine Connections
https://read.qxmd.com/read/33432541/patient-and-healthcare-provider-perspectives-of-first-generation-somatostatin-analogs-in-the-management-of-neuroendocrine-tumors-and-acromegaly-a-systematic-literature-review
#2
REVIEW
David Cella, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S Khan
INTRODUCTION: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate which characteristics beyond efficacy are most important in patient and healthcare practitioner (HCP) experience of LAN and OCT when used to treat acromegaly and NETs. METHODS: MEDLINE, Embase, the Cochrane Library, and Database of Abstracts of Reviews of Effect were searched from database inception to January 2019 with terms for first-generation SSAs, NETs, acromegaly, preferences, decision-making, and human factors...
January 11, 2021: Advances in Therapy
https://read.qxmd.com/read/33421978/systemic-treatment-of-advanced-gastroenteropancreatic-neuroendocrine-tumors-in-korea-literature-review-and-expert-opinion
#3
Changhoon Yoo, Chung Ryul Oh, Seung-Tae Kim, Woo Kyun Bae, Hye-Jin Choi, Do-Youn Oh, Myung-Ah Lee, Baek-Yeol Ryoo
Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients...
December 29, 2020: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://read.qxmd.com/read/33393112/novel-tumor-growth-rate-analysis-in-the-randomized-clarinet-study-establishes-the-efficacy-of-lanreotide-depot-autogel-120-mg-with-prolonged-administration-in-indolent-neuroendocrine-tumors
#4
Clarisse Dromain, Arturo Loaiza-Bonilla, Beloo Mirakhur, Thomas J R Beveridge, Antonio Tito Fojo
INTRODUCTION: Tumor quantity while receiving cancer therapy is the sum of simultaneous regression of treatment-sensitive and growth of treatment-resistant fractions at constant rates. Exponential rate constants for tumor regression/decay (d) and growth (g) can be estimated. Previous studies established g as a biomarker for overall survival; g increases after treatment cessation, can estimate doubling times and can assess treatment effectiveness in small cohorts by benchmarking to large reference data sets...
January 3, 2021: Oncologist
https://read.qxmd.com/read/33369374/-the-use-of-long-acting-somatostatin-analogs-in-congenital-hyperinsulinism
#5
E E Novokreshhennyx, D N Gubaeva, M A Melikyan
BACKGROUND: Children with congenital hyperinsulinism (CHI), a severe orphan disease, are still one of the most demanding patients in the endocrinology practice. The use of first- and second-line drugs is not always effective and has a number of restrictions. Lanreotide - long-acting somatostatin - represents an alternative insulinostatic therapy. The main advantage of lanreotide is stable concentration of the drug in the blood that enables minimizing the number of injections. However, the experience of using lanreotide in the treatment of CHI is limited to small groups of patients...
October 24, 2020: Problemy E̊ndokrinologii
https://read.qxmd.com/read/33351318/-epidemiology-clinical-manifestations-and-efficiency-of-different-methods-of-treatment-of-acromegaly-according-to-the-united-russian-registry-of-patients-with-pituitary-tumors
#6
Zhanna E Belaya, Olga O Golounina, Liudmila Y Rozhinskaya, Galina A Melnichenko, Michail А Isakov, Alexander S Lutsenko, Tatiana Alekseeva, Tatiana S Zenkova, Elena G Przhiyalkovskaya, Galina M Panyushkina, Olga B Ilukhina, Elena I Ivanova, Ekaterina A Krishtal, Alla A Vachygova, Ekaterina A Pigarova, Larisa K Dzeranova, Evgenia I Marova, Svetlana D Arapova, Elizaveta O Mamedova, Tatiana A Grebennikova, Mikhail B Antsiferov, Alexander V Dreval, Ivan I Dedov
BACKGROUND: The registry is the main source of information about patients with acromegaly for assessing the quality of medical care, effectiveness of treatment, determining the compliance of real clinical practice with existing standards and patient management protocols. AIMS: To evaluate epidemiological, demographic and clinical characteristics of acromegaly in Russian Federation and effectiveness of treatment modalities. MATERIALS AND METHODS: The object of the study was the database of the united Russian registry of patients with pituitary tumors with specific analysis of patients with acromegaly only...
August 4, 2020: Problemy E̊ndokrinologii
https://read.qxmd.com/read/33329885/somatostatin-analogues-for-the-treatment-of-hyperinsulinaemic-hypoglycaemia
#7
REVIEW
Basma Haris, Saras Saraswathi, Khalid Hussain
Hyperinsulinaemic hypoglycaemia (HH) is a biochemical finding of low blood glucose levels due to the dysregulation of insulin secretion from pancreatic β-cells. Under normal physiological conditions, glucose metabolism is coupled to β-cell insulin secretion so that blood glucose levels are maintained within the physiological range of 3.5-5.5 mmol/L. However, in HH this coupling of glucose metabolism to insulin secretion is perturbed so that insulin secretion becomes unregulated. HH typically occurs in the neonatal, infancy and childhood periods and can be due to many different causes...
2020: Therapeutic Advances in Endocrinology and Metabolism
https://read.qxmd.com/read/33301235/somatostatin-analogs-for-pancreatic-neuroendocrine-tumors-any-benefit-when-ki-67-is-%C3%A2-10
#8
E Merola, T Alonso Gordoa, P Zhang, T Al-Toubah, E Pelle, A Kolasińska-Ćwikła, W T Zandee, F M Laskaratos, L de Mestier, A Lamarca, J Hernando, J B Cwikla, J Strosberg, W W de Herder, M Caplin, M Cives, R S van Leeuwaarde
BACKGROUND: Long-acting somatostatin analogs (SSAs) are the primary first-line treatment of well-differentiated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki-67 ≥10% are still limited. MATERIALS AND METHODS: To assess the clinical outcomes of advanced, non-functioning, well-differentiated panNETs with Ki-67 ≥10% receiving first-line long-acting SSAs in a real-world setting, we carried out a retrospective, multi-center study including patients treated between 2014-2018 across ten centers of the NET CONNECT Network...
December 10, 2020: Oncologist
https://read.qxmd.com/read/33289697/presurgical-somatostatin-receptor-ligands-treatment-does-not-affect-tumor-consistency-in-gh-secreting-pituitary-macroadenomas
#9
Marta Araujo-Castro, Héctor Pian, Ignacio Ruz-Caracuel, Alberto Acitores Cancela, Eider Pascual-Corrales, Víctor Rodríguez Berrocal
PURPOSE: To evaluate whether pre-surgical treatment using long-acting somatostatin receptor ligands (SRL) may change pituitary tumor consistency and improve surgical outcome in GH-secreting pituitary macroadenomas. METHODS: Retrospective study of 40 patients with GH-secreting pituitary macroadenomas operated for the first time by endoscopic transsphenoidal approach. Tumor consistency was evaluated intraoperatively and then correlated with histopathological fibrosis parameters and surgical outcomes...
December 1, 2020: Endocrine Connections
https://read.qxmd.com/read/33285601/multicenter-observational-study-of-lanreotide-autogel-for-the-treatment-of-patients-with-acromegaly-in-routine-clinical-practice-in-germany-austria-and-switzerland
#10
Sylvère Störmann, Jochen Schopohl, Catharina Bullmann, Christoph Terkamp, Mirjam Christ-Crain, Reinhard Finke, Jörg Flitsch, Ilonka Kreitschmann-Andermahr, Anton Luger, Günter Stalla, Aude Houchard, Dorit Helbig, Stephan Petersenn
BACKGROUND: Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the real-world patient population receiving lanreotide autogel treatment. METHODS: In this non-interventional study the long-term treatment response to lanreotide autogel in adult patients with acromegaly from office-based centers or clinics in Germany, Austria and Switzerland was studied...
December 7, 2020: Experimental and Clinical Endocrinology & Diabetes
https://read.qxmd.com/read/33199989/missed-diagnosis-and-delayed-treatment-of-acromegaly-in-a-patient-with-severe-diabetes-a-case-report
#11
Kota Nishihama, Yutaka Yano, Taro Yasuma, Esteban C Gabazza
The early stages of acromegaly are characterized by slow and progressive acral overgrowth without major systemic complications. Failure to diagnose acromegaly at an early stage may have devastating consequences on patient care. The case in the present report was a 44-year-old Japanese man, referred to Kuwana City Medical Center due to severe hyperglycemia detected in a general checkup. The patient had no acromegaly-related complaints. Laboratory data revealed high blood levels of hemoglobin A1c and glucose...
December 2020: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/33164134/biliary-adverse-events-in-acromegaly-during-somatostatin-receptor-ligands-predictors-of-onset-and-response-to-ursodeoxycholic-acid-treatment
#12
N Prencipe, C Bona, D Cuboni, M Parasiliti-Caprino, A M Berton, L M Fenoglio, V Gasco, E Ghigo, S Grottoli
PURPOSE: Somatostatin receptor ligands (SRL) are the first-line medical treatment for acromegaly. Gallbladder alterations are one of most important SRL side effect, but according to some authors growth hormone hypersecretion itself is a risk factor for gallstones. This single center, longitudinal retrospective study evaluated the incidence and the predictors of biliary adverse events (BAE) in acromegaly during SRL therapy and their response to ursodeoxycholic acid (UDCA). METHODS: 91 acromegaly patients with indication to SRL were enrolled...
November 9, 2020: Pituitary
https://read.qxmd.com/read/33121847/do-somatostatin-analogues-have-the-same-impact-on-postoperative-morbidity-and-pancreatic-fistula-in-patients-after-pancreaticoduodenectomy-and-distal-pancreatectomy-a-systematic-review-with-meta-analysis-of-randomized-controlled-trials
#13
Stephan Schorn, Thomas Vogel, Ihsan Ekin Demir, Elke Demir, Okan Safak, Helmut Friess, Güralp Onur Ceyhan
OBJECTIVE: Postoperative pancreatic fistula/POPF is the most feared complication in pancreatic surgery. Although several systematic reviews investigated the impact of somatostatin analogues on POPF, no stratification was performed regarding type of pancreatic resection (pancreaticoduodenectomy/PD; distal pancreatectomy/DP) and different somatostatin analogues. METHODS: This study was planed according to the Preferred-Reporting-Items-for-Systematic -Review-and-Meta-Analysis/PRISMA-guidelines...
October 22, 2020: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://read.qxmd.com/read/33082756/benign-appearing-glucagonoma-undergoing-malignant-transformation-after-a-prolonged-period
#14
Mohamed K M Shakir, Ismail C Ebrahim, Andrea N Snitchler, Vinh Q Mai, Thanh D Hoang
Glucagonoma are rare neuroendocrine tumors arising in the Langerhans islets of the pancreas. We report a patient with glucagonoma differentiation into a malignant form after 13 years. A 63-year-old asymptomatic man was evaluated for an enhancing lesion at the distal pancreas. Physical examination was normal. Laboratory values were normal except for an elevated serum glucagon level (206 pg/mL, Ref. 50-150). Somatostatin and other tumor markers were normal. A PET scan confirmed abnormal uptake at the distal pancreas, correlating with a CT scan...
September 2020: Case Reports in Oncology
https://read.qxmd.com/read/33075795/efficacy-of-a-novel-second-generation-somatostatin-dopamine-chimera-tbr-065-in-human-medullary-thyroid-cancer-a-preclinical-study
#15
Alessandra Dicitore, Maria Celeste Cantone, Germano Gaudenzi, Davide Saronni, Silvia Carra, Maria Orietta Borghi, Manuela Albertelli, Diego Ferone, Leo J Hofland, Luca Persani, Giovanni Vitale
INTRODUCTION: Somatostatin and dopamine receptors have a pivotal role in control of hormone secretion and cell proliferation in different neuroendocrine neoplasms, including medullary thyroid cancer (MTC). In the present preclinical study, we evaluated the antitumor activity of TBR-065 (formerly BIM-23B065), a second-generation somatostatin-dopamine chimera, in two human MTC cell lines. METHODS: the effects of lanreotide (LAN) and TBR-065 on the cell growth proliferation, calcitonin secretion, cell cycle, apoptosis, cell migration and tumor-induced angiogenesis have been evaluated through MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, ECLIA assay, wound-healing assay and zebrafish platform, respectively...
October 19, 2020: Neuroendocrinology
https://read.qxmd.com/read/33074400/the-effect-of-somatostatin-analogs-and-acromegaly-on-the-upper-gastrointestinal-system
#16
Serdar Sahin, Tevhide Betul Icli, Emre Durcan, Cem Sulu, Hande Mefkure Ozkaya, Ali Ibrahim Hatemi, Pinar Kadioglu
PURPOSE: To evaluate the effects of somatostatin analogs and disease activity status on the upper gastrointestinal system in patients with acromegaly. METHODS: One hundred eighty-one patients with acromegaly were retrospectively assessed. The demographic, biochemical, pathologic, and radiologic data of the patients were evaluated. The upper gastrointestinal endoscopies and endoscopic biopsies were investigated. We divided patients into four groups according to the use of somatostatin analogs, and into two groups according to disease activity...
October 19, 2020: Pituitary
https://read.qxmd.com/read/33052555/lanreotide-autogel-depot-in-advanced-enteropancreatic-neuroendocrine-tumours-final-results-of-the-clarinet-open-label-extension-study
#17
Martyn E Caplin, Marianne Pavel, Alexandria T Phan, Jarosław B Ćwikła, Eva Sedláčková, Xuan-Mai Truong Thanh, Edward M Wolin, Philippe Ruszniewski
PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). The aim of CLARINET open-label extension (OLE) (NCT00842348) was to evaluate long-term safety and efficacy of lanreotide in these patients. METHODS: Patients from the CLARINET study were eligible for the OLE if they had stable disease (irrespective of treatment group) or progressive disease (PD) (placebo-treated patients only)...
October 14, 2020: Endocrine
https://read.qxmd.com/read/32942893/cushings-syndrome-and-acromegaly-based-on-picoadenoma-of-the-pituitary-gland
#18
Ivana Ságová, Daniela Kantárová, Dušan Pávai, Milan Dragula, Anton Vaňuga, Peter Vaňuga
Cushings syndrome (CS) is a relatively rare disease characterized by autonomous hypersecretion of cortisol. The incidence of CS is estimated to be equal to 2-3 cases per million inhabitants per year. The incidence of acromegaly is 3-4 patients per 1 000 000 per year. The disease is caused by hypersecretion of growth hormone which is mainly caused by benign tumour of the pituitary gland. In our case report we present a 41- year old woman suffering from both Cushings syndrome and acromegaly. The patient was examined in National Institute of Endocrinology and Diabetology Ľubochňa for a centripetal type of obesity and hirsutism...
2020: Vnitr̆ní Lékar̆ství
https://read.qxmd.com/read/32919636/electrostatically-bound-lanreotide-peptide-gold-nanoparticle-conjugates-for-enhanced-uptake-in-sstr2-positive-cancer-cells
#19
Sandeep B Shelar, Santosh L Gawali, Kanhu C Barick, Amit Kunwar, Arivozhi Mohan, Indira K Priyadarsini, Puthusserickal A Hassan
Lanreotide peptide (LP) has high affinity to somatostatin receptors like SSTR2 and is commonly used in the treatment of neuro-endocrine tumors. The main objective of this study is to target gold nanoparticles (AuNPs) towards SSTR2-positive cancer cells using lanreotide peptide (LP) as the targeting agent for enhanced tumor uptake and antitumor activity. pH mediated changes in the surface potential of LP and AuNP is used to prepare electrostatically bound AuNP-LP complexes. AuNP-LP complex formation was demonstrated by UV-Visible spectroscopy, surface potential, dynamic light scattering (DLS), small angle X-ray scattering and HR-TEM...
December 2020: Materials Science & Engineering. C, Materials for Biological Applications
https://read.qxmd.com/read/32914327/intestinal-occlusion-by-gynecological-cancers-treated-by-percutaneous-endoscopic-gastrostomy-and-lanreotide-an-aviano-national-cancer-institute-experience
#20
Martina Budel, Luca Martella, Laura Zambon, Isabella Morson, Giorgio Giorda, Renato Cannizzaro
The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients...
September 10, 2020: Supportive Care in Cancer
keyword
keyword
81166
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"